A Phase 4 interventional study of LipiFlow Thermal Pulsation and Dexamethasone Intracanalicular Insert, 0.4mg with LipiFlow Thermal Pulsation in Dry Eye Syndromes, sponsored by Eye Surgeons of Indiana. Completed at 1 site in United States. Per ClinicalTrials.gov, last updated 2026-11-10.
Sponsored by Eye Surgeons of Indiana · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies testing dexamethasone in Dry Eye Syndromes — none open to participants now, none under way, none of them phase 3. Dexamethasone · Dry Eye Syndromes.
Among the 16 studies testing dexamethasone in Dry Eye Syndromes, this one is the 14th largest by enrollment, is one of 5 that started in 2020, is one of 12 in phase 4, and was the 9th registered.
1,370 studies on the registry are indexed under Dry Eye Syndromes; 209 are open to participants now.
Browse Dry Eye Syndromes studies →None of the 16 studies testing dexamethasone in Dry Eye Syndromes is open now. The open studies under Dry Eye Syndromes, anywhere →
Dexamethasone: first FDA approval 1958 (DECADRON), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →
Of the 117 Dry Eye Syndromes studies recruiting now, 74 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 5 started in 2020.
This study's enrollment of 20 is below the median of 60 across 1,132 interventional studies indexed under Dry Eye Syndromes.
Median enrollment 36 across the 16 interventional studies. Of the 14 that completed or were terminated, 8 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 16 have an industry lead sponsor. The 10 most frequent:
Eye Surgeons of Indiana is the lead sponsor of 2 studies on the registry; none are open to participants now.
Eye Surgeons of Indiana has 2 studies filed under Dry Eye Syndromes — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 16 studies testing dexamethasone in Dry Eye Syndromes, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To evaluate the benefit of treatment with a physician administered intracanalicular dexamethasone insert in evaporative dry eye disease (DED) patients with meibomian gland disfunction (MGD) and underlying inflammation undergoing LipiFlow Thermal Pulsation.
This prospective, open-label, single-center, non-randomized, investigator-sponsored clinical study seeks to investigate the benefit of managing patients with DED secondary to MGD with a sustained release intracanalicular dexamethasone (0.4 mg) insert in addition to LipiFlow Thermal Pulsation compared to LipiFlow Thermal Pulsation alone. In addition, this study will evaluate the ease of Dextenza insertion and the patient preference for therapy.
After screening a given patient for inclusion and exclusion criteria, and gaining informed consent, each eye will undergo LipiFlow Thermal Pulsation on the same day. The most symptomatic eye will be selected to receive DEXTENZA® insertion on the day of the procedure (study eye), while the other eye will be assigned to a receive a sham punctum dilation (control eye). If there is no obvious symptomatic difference, the right eye will receive the intracanalicular insert. Per patient, the study period will last for approximately 12 weeks after the LipiFlow procedure, consisting of one screening visit, one treatment v4isit and 3 post-procedure follow-up visits (week 1, week 4 and week 12). At week 1, week 4 and week 12, primary and secondary endpoints will be assessed alongside standard-of-care procedures. Adjusting for enrollment period, the study will last a total of approximately 4 months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
A patient's study eye must meet the following criteria to be eligible for inclusion in the study:
Exclusion Criteria:
A patient who meets any of the following criteria will be excluded from the study:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients with dry eye disease Lipiflow only
Procedure: LipiFlow Thermal Pulsation
Patients with dry eye disease Lipiflow + Dextenza
Drug: Dexamethasone Intracanalicular Insert, 0.4mg with LipiFlow Thermal Pulsation
To manage patients with dry eye disease secondary to MGD
Drug page: DexamethasoneStudies of DexamethasoneDexamethasone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
to investigate the benefit of managing patients with DED secondary to MGD with a sustained release intracanalicular dexamethasone (0.4 mg) insert in addition to LipiFlow Thermal Pulsation
Also known as: Dextenza
Change From Baseline in Meibomian Gland Scores (Expressibility and Quality)
Meibomian gland expressibility was graded at the slit lamp using the methodology of the pivotal LipiFlow trial. Fifteen glands of the lower eyelid (5 temporal, 5 central, 5 nasal) were each graded on a 0-3 scale (0 = no secretion; 1 = inspissated/toothpaste-like secretion; 2 = cloudy liquid secretion; 3 = clear liquid secretion). Grades were summed to produce a composite Meibomian Gland Expressibility Score ranging from 0 to 45. Higher scores indicate better meibomian gland function. Values shown are the mean score at each study visit.
Time frame: Assessed at Baseline, Week 1, Week 4 and Week 12
Patient Preference
As measured by COMTOL Survey
Time frame: Assessed at Week 12
The Rate of Positive MMP-9
Meibomian gland inflammation was assessed using the InflammaDry point-of-care immunoassay, which detects elevated matrix metalloproteinase-9 (MMP-9) levels in tear fluid. Results are reported as positive or negative based on a predefined assay threshold. The outcome represents the proportion of eyes testing positive for MMP-9 at each study visit.
Time frame: Assessed at Baseline, Week 1, Week 4 and Week 12 Visit
Mean Change in Ocular Surface Staining
Corneal fluorescein staining was graded on a 0-3 scale (none to heavy) in 5 corneal regions (superior, inferior, nasal, temporal, central) and summed for a corneal score (range 0-15). Conjunctival lissamine green staining was graded on the same 0-3 scale in 6 conjunctival regions (3 nasal, 3 temporal) and summed for a conjunctival score (range 0-18). Corneal and conjunctival scores were summed to produce a total Ocular Surface Staining Score ranging from 0 to 33. Higher scores indicate greater ocular surface damage (worse outcome). Values shown are the mean score at each study visit.
Time frame: Assessed at Baseline, Week 1, Week 4 and Week 12 Visit
Mean Change in Tear Break-up Time (TBUT)
Tear break-up time (TBUT) was measured in seconds following fluorescein instillation as the interval between a complete blink and the first appearance of tear film disruption. Higher TBUT values indicate greater tear film stability. Values shown are the mean TBUT at each study visit.
Time frame: Assessed at Baseline, Week 1, Week 4 and Week 12 Visit
Mean Change in Tear Osmolarity (mOsm/L)
Tear osmolarity was measured using a point-of-care tear osmolarity system and reported in milliosmoles per liter (mOsm/L). Higher values indicate greater tear film hyperosmolarity and ocular surface stress. Values shown are the mean tear osmolarity at each study visit.
Time frame: Assessed at Baseline, Week 1, Week 4 and Week 12 Visit
Mean Change in DEQ-5
Dry eye symptoms were assessed using the Dry Eye Questionnaire-5 (DEQ-5), a validated patient-reported outcome instrument with scores ranging from 0 to 22. Higher DEQ-5 scores indicate greater severity of dry eye symptoms. The outcome represents the mean change in DEQ-5 score from baseline at each study visit.
Time frame: Assessed at Baseline, Week 1, Week 4 and Week 12 Visit
Mean Change in Best-corrected Visual Acuity (BCVA)
Best-corrected visual acuity (BCVA) was measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) chart and recorded as the number of letters read correctly (range 0 to 100 letters). Higher letter scores indicate better visual acuity. Values shown are the mean BCVA letter score at each study visit.
Time frame: Assessed at Baseline, Week 1, Week 4 and Week 12 Visit
| Milestone | Lipiflow Only Eye | Lipiflow + Dextenza Eye |
|---|---|---|
| Started | 20 | 20 |
| Completed | 19 | 19 |
| Not completed | 1 | 1 |
Meibomian gland expressibility was graded at the slit lamp using the methodology of the pivotal LipiFlow trial. Fifteen glands of the lower eyelid (5 temporal, 5 central, 5 nasal) were each graded on a 0-3 scale (0 = no secretion; 1 = inspissated/toothpaste-like secretion; 2 = cloudy liquid secretion; 3 = clear liquid secretion). Grades were summed to produce a composite Meibomian Gland Expressibility Score ranging from 0 to 45. Higher scores indicate better meibomian gland function. Values shown are the mean score at each study visit.
| score on a scale | Lipiflow Only Eye | Lipiflow + Dextenza Eye |
|---|---|---|
| Baseline | 16.3 ± 8.0 | 13.3 ± 8.1 |
| Week 1 | 26.4 ± 11.5 | 26.8 ± 12.8 |
| Week 4 | 29.7 ± 11.1 | 29.3 ± 10.9 |
| Week 12 | 27.3 ± 11.4 | 29.8 ± 9.9 |
As measured by COMTOL Survey
| Participants | Total Participants |
|---|---|
| Preferred Lipiflow and SHAM | 7 |
| Preferred Lipiflow and DEXTENZA | 11 |
| Had no preference | 1 |
Meibomian gland inflammation was assessed using the InflammaDry point-of-care immunoassay, which detects elevated matrix metalloproteinase-9 (MMP-9) levels in tear fluid. Results are reported as positive or negative based on a predefined assay threshold. The outcome represents the proportion of eyes testing positive for MMP-9 at each study visit.
| eyes | Lipiflow Only Eye | Lipiflow + Dextenza Eye |
|---|---|---|
| Baseline | 15 | 16 |
| Week 1 | 12 | 10 |
| Week 4 | 9 | 13 |
| Week 12 | 9 | 13 |
Corneal fluorescein staining was graded on a 0-3 scale (none to heavy) in 5 corneal regions (superior, inferior, nasal, temporal, central) and summed for a corneal score (range 0-15). Conjunctival lissamine green staining was graded on the same 0-3 scale in 6 conjunctival regions (3 nasal, 3 temporal) and summed for a conjunctival score (range 0-18). Corneal and conjunctival scores were summed to produce a total Ocular Surface Staining Score ranging from 0 to 33. Higher scores indicate greater ocular surface damage (worse outcome). Values shown are the mean score at each study visit.
| score on a scale | Lipiflow Only Eye | Lipiflow + Dextenza Eye |
|---|---|---|
| Baseline | 5.2 ± 4.7 | 6.6 ± 6.3 |
| Week 1 | 5.6 ± 4.7 | 4.5 ± 5.9 |
| Week 4 | 3.8 ± 4.3 | 3.6 ± 4.6 |
| Week 12 | 6.2 ± 6.5 | 5.7 ± 5.9 |
Tear break-up time (TBUT) was measured in seconds following fluorescein instillation as the interval between a complete blink and the first appearance of tear film disruption. Higher TBUT values indicate greater tear film stability. Values shown are the mean TBUT at each study visit.
| seconds | Lipiflow Only Eye | Lipiflow + Dextenza Eye |
|---|---|---|
| Baseline | 4.1 ± 3.4 | 3.2 ± 2.2 |
| Week 1 | 4.6 ± 3.3 | 4.9 ± 4.6 |
| Week 4 | 6.1 ± 5.5 | 6.3 ± 5.8 |
| Week 12 | 4.7 ± 3.4 | 6.1 ± 4.8 |
Tear osmolarity was measured using a point-of-care tear osmolarity system and reported in milliosmoles per liter (mOsm/L). Higher values indicate greater tear film hyperosmolarity and ocular surface stress. Values shown are the mean tear osmolarity at each study visit.
| mOsm/L | Lipiflow Only Eye | Lipiflow + Dextenza Eye |
|---|---|---|
| Baseline | 309.1 ± 12.5 | 305 ± 8.8 |
| Week 1 | 313.5 ± 14.8 | 305.1 ± 9.5 |
| Week 4 | 310.5 ± 18.6 | 309.1 ± 18.6 |
| Week 12 | 310.8 ± 18.0 | 307.6 ± 15.5 |
Dry eye symptoms were assessed using the Dry Eye Questionnaire-5 (DEQ-5), a validated patient-reported outcome instrument with scores ranging from 0 to 22. Higher DEQ-5 scores indicate greater severity of dry eye symptoms. The outcome represents the mean change in DEQ-5 score from baseline at each study visit.
| score on a scale | Total Participants |
|---|---|
| Baseline | 12.3 ± 4.4 |
| Week 1 | 11.1 ± 4.7 |
| Week 4 | 10.3 ± 5.1 |
| Week 12 | 9.1 ± 5.9 |
Best-corrected visual acuity (BCVA) was measured using the Early Treatment Diabetic Retinopathy Study (ETDRS) chart and recorded as the number of letters read correctly (range 0 to 100 letters). Higher letter scores indicate better visual acuity. Values shown are the mean BCVA letter score at each study visit.
| letters | Lipiflow Only Eye | Lipiflow + Dextenza Eye |
|---|---|---|
| Baseline | 85.8 ± 4.4 | 85.7 ± 4.1 |
| Week 1 | 86.2 ± 3.8 | 86.3 ± 5.1 |
| Week 4 | 86.3 ± 4.0 | 85.9 ± 5.2 |
| Week 12 | 86.0 ± 3.6 | 83.9 ± 14.0 |
Collected over Baseline through Week 12. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Lipiflow Only Group | 0/19 (0%) | 0/19 (0%) | 0/19 (0%) |
| Lipiflow + Dextenza Group | 0/19 (0%) | 0/19 (0%) | 0/19 (0%) |
Adults aged 18 years or older with history of evaporative dry eye disease, meibomian gland dysfunction, and clinically significant inflammation as evidenced by ocular surface staining and/or conjunctival hyperemia and/or elevated MMP-9 levels. Exclusion criteria included ocular or nonocular infection, compromised nasolacrimal flow, or concurrent use of or contraindications to corticosteroids
| Age, Continuous(years) | Participants Had Lipiflow in Both Eyes and DEXDENZA in One Eye |
|---|---|
| Mean | 59.2 ± 11.1 |
| Sex: Female, Male(Participants) | Participants Had Lipiflow in Both Eyes and DEXDENZA in One Eye |
|---|---|
| Female | 18 |
| Male | 2 |
| Race (NIH/OMB)(Participants) | Participants Had Lipiflow in Both Eyes and DEXDENZA in One Eye |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 0 |
| White | 19 |
| More than one race | 0 |
| Unknown or Not Reported | 1 |
| Region of Enrollment(participants) | Participants Had Lipiflow in Both Eyes and DEXDENZA in One Eye |
|---|---|
| United States | 20 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Aug 2020 to primary completion in Jul 2021, 11 months.
Results were first posted in Nov 2026, 5 years 4 months after primary completion.
Of 85 non-industry phase 4 interventional studies under Dry Eye Syndromes, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 28. This study's 11 months is below that.
Counting every sponsor, half of 113 studies reached it within 12 months; a quarter within 5 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dexamethasone
Eye Surgeons of Indiana